Oxford Covid-19 Vaccine Early Trial: What the 2020 Results Showed

Facebook ↗WhatsApp ↗

Originally published 2020-07-21.

Oxford's Early COVID-19 Vaccine Immune-Response Results

Trial samples being handled in the Oxford Vaccine Group laboratory at the University of Oxford. Photo: John Cairns/AP.

On 20 July 2020, researchers at the University of Oxford published the first results from human testing of their Covid-19 vaccine, then known as ChAdOx1 nCoV-19. The headline finding was that the vaccine was safe enough to keep testing and that it prompted two kinds of immune response at once: neutralising antibodies, which can block the virus from entering cells, and T-cells, which help the body find and destroy infected cells.

What the results did not show, and could not show at that stage, was whether the vaccine actually stopped people from catching Covid-19 or becoming seriously ill. That answer came later, from much bigger trials. This piece explains what the early data said, why scientists were encouraged, and how the story ended.

What the July 2020 trial found

The phase 1/2 study, published in The Lancet, enrolled 1,077 healthy adults aged 18 to 55 at five sites in the UK between late April and late May 2020. Roughly half received the Oxford vaccine and the rest received an existing meningitis vaccine (MenACWY) as a comparison, so that volunteers did not know which shot they had been given.

  • Antibodies: neutralising antibodies were detected in about 91% of a tested subgroup after a single dose, and in all ten volunteers who were given a second, booster dose.
  • T-cells: T-cell responses rose quickly and peaked around 14 days after vaccination.
  • Safety: there were no serious vaccine-related side effects. Fatigue and headache were the most common complaints, along with sore arms, chills and mild fever, and these usually faded within a day or two. Taking paracetamol around the time of the jab reduced them.

Oxford’s Covid-19 vaccine produces a good immune response, reveals new study.
Teams at @VaccineTrials and @OxfordVacGroup have found there were no safety concerns, and the vaccine stimulated strong immune responses: https://t.co/krqRzXMh7B pic.twitter.com/Svd3MhCXWZ

— University of Oxford (@UniofOxford) July 20, 2020

(This post is no longer available on X.)

How the Oxford vaccine works

The vaccine uses what is called a viral vector. The researchers started with a weakened adenovirus, a type of common-cold virus that infects chimpanzees, and altered it so that it cannot multiply in people. Into it they inserted the genetic instructions for the coronavirus "spike" protein, the structure the virus uses to latch onto human cells.

Once injected, the vector delivers those instructions to some of the body's cells, which then briefly produce spike protein. The immune system recognises the spike as foreign and builds a response against it, without the person ever being exposed to the actual coronavirus. The same platform had already been tested in earlier Oxford work on other diseases, which is one reason the team could move unusually fast.

Oxford's Early COVID-19 Vaccine Immune-Response Results

Samples from volunteers are analysed in the lab as part of the trial, measuring antibody and T-cell levels at set points after vaccination.

Why scientists were cautious

An immune response is an encouraging sign, but it is not the same as protection. In mid-2020 nobody yet knew what level of antibodies or T-cells was enough to stop infection or severe disease. The volunteers were also young and healthy, while the people most at risk from Covid-19 were older adults and those with other conditions.

The researchers said this plainly. Sarah Gilbert, the Oxford professor who led the vaccine's design, said there was still much work to be done before the team could confirm whether it would help manage the pandemic. Andrew Pollard, director of the Oxford Vaccine Group, told the BBC the key question was whether the vaccine offered protection, adding that the team was in a waiting game.

To answer that, the vaccine had to be tested in thousands of people living where the virus was spreading widely. Trials were expanded in the UK and launched in Brazil, South Africa and later the United States. At the time there was also public discussion of "human challenge" studies, in which vaccinated volunteers are deliberately exposed to the virus to get faster answers. These raise serious ethical questions, especially before effective treatments exist, and they were not used to test this vaccine.

The UK's early bet on 100 million doses

Even before the July results, the UK government had ordered 100 million doses, and Oxford had partnered with the drug company AstraZeneca to manufacture at scale. Production began "at risk", meaning before anyone knew whether the vaccine would work. If it had failed, those doses would have been wasted. Because it succeeded, supplies were ready far sooner than in a normal development timeline.

AstraZeneca also agreed to supply the vaccine on a not-for-profit basis during the pandemic. That, together with the fact that it could be stored in an ordinary refrigerator rather than a deep freezer, made it especially important for lower-income countries.

What happened after the early results

The larger trials delivered their first efficacy figures in November 2020. An interim analysis reported about 70% protection against symptomatic Covid-19 overall, but the number combined two dosing schedules, one of which had been given by mistake at half strength. That mix-up drew criticism, and later, cleaner analyses reported efficacy of around 76% after a single dose and higher when the second dose was given 12 or more weeks later. A US trial reported 74% efficacy against symptomatic disease in 2021.

  • 30 December 2020: the UK approved the vaccine for emergency use.
  • 4 January 2021: the first doses outside trials were given in the UK.
  • 2021 to 2023: more than three billion doses were supplied worldwide, many of them to lower-income countries through the global COVAX scheme.

The rare clotting side effect

In spring 2021, regulators identified a very rare but serious side effect: blood clots combined with low platelet counts, known as thrombosis with thrombocytopenia syndrome (TTS). It occurred in roughly one in 100,000 vaccinated people and was seen more often in younger adults. Many countries responded by recommending other vaccines for younger age groups while continuing to use this one for older people, for whom the benefit clearly outweighed the risk.

As newer vaccines adapted to later variants became available, demand fell, and AstraZeneca withdrew the vaccine from the market in 2024. It is no longer produced. Anyone with questions about their own vaccination history or side effects should talk to a doctor.

Why the July 2020 results mattered

Looking back, the first Oxford paper was a milestone rather than a finish line. It showed that a vaccine built in a matter of months could be given safely and could train the immune system against the new coronavirus. That gave scientists, manufacturers and governments the confidence to invest in the huge trials and production lines that followed. The story is also a reminder of how science works in a crisis: early results are promising signals, and the real answer comes from larger, slower studies.

Sources: Folegatti et al., The Lancet (2020); Wikipedia: Oxford–AstraZeneca COVID-19 vaccine; BBC News, July 2020; ITV News, July 2020. Lead photo: John Cairns/AP.

COMMENTS